BOSTON, 29 August 2024 /PRNewswire/ — In August 2024, Medicilon USA Corp (Medicilon) has officially started operations at its second research and development center in Massachusetts, USA. Research at the new facility will focus on animal models for PK/PD and toxicology studies. This milestone marks the beginning of Medicilon’s continued global business expansion.
The Lexington, Massachusetts The location was chosen to improve synergies and communication with industrial partners
Medicilon’s second R&D center in Massachusetts
Medicilon aims to increase its contribution to pharmaceutical innovation by leveraging its proximity to numerous leading biotech companies and research institutions. Lexington The site will provide essential research services while ensuring seamless communication with both industry-based and academic drug development teams. Medicilon’s commitment to quality and innovation will also ensure the competitiveness of its research partners in the development of new therapeutic technologies.
The The US R&D service matrix has been updated to enable accelerated development of novel drug modalities
The new laboratory complements Medicilon’s diverse R&D platforms with state-of-the-art resources. The research center uses modern instrumentation and animal laboratories and has access to an extensive animal model library (including over 410 tumor efficacy models and over 240 non-tumor animal models). The site’s top scientists perform efficacy evaluations of small molecule drugs and biologics, as well as pharmacokinetic evaluations and optimization. Studies are conducted in accordance with ICH, NMPA and FDA standards.
Since Medicilon began submitting preclinical approval applications that meet both Chinese and US GLP standards, the team has gradually built up an international collaboration network. The initial presence in Boston was founded in 2016 and offers business activities in the United States. Medicilon has already started local research projects for key partners in the United States by 2023. The expansion of the R&D center in Massachusetts will significantly enhance Medicilon’s international service capabilities. This move reflects Medicilon’s proactive response to the constant changes in drug development trends.
Dr. Qingcong Lin, President of Medicilon USAannounced: “Boston“With its world-class pharmaceutical innovation and technology resources, China is a strategic choice for Medicilon to strengthen its presence. Medicilon will leverage local advantages to stimulate internal potential, strengthen technological capabilities and explore new fields in drug development through innovation and collaboration.”
Dr. Chen ChunlinFounder and CEO of Medicilon, announced: “With the R&D center in Boston, Medicilon will build closer ties with the global pharmaceutical innovation ecosystem and continuously drive technological innovation and service improvement. We are committed to becoming a globally trusted, comprehensive CRO for preclinical research services in the pharmaceutical industry.”
Photo – https://mma.prnewswire.com/media/2492413/Medicilon_s_Second_R_D_Center_Massachusetts.jpg
